- Cambridge, Massachusetts
- Research Interests:
DNA Structure and Protein Expression, Cell Differentiation and Epigenetics, Histone Modifying Enzymes, Epigenetics in Human Diseases, Kinase Analogy to HMTs
- About Epizyme:
- Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients, based on breakthroughs in the field of epigenetics. Epigenetic enzymes are strongly associated with the underlying causes of multiple human diseases and have been broadly validated as viable drug targets by the FDA approval of histone deacetylase and DNA methyltransferase enzyme inhibitors. Our patient-driven approach to the creation of personalized therapeutics represents the future of cancer therapy creating better therapeutics for the right patients more quickly and at lower cost than traditional approaches. Epizyme's personalized therapeutics are exemplified by our two most advanced therapeutic product programs, targeting the HMTs DOT1L and EZH2.